{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-012308","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2022-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.270315+00:00","generated_at":"2026-06-25T23:13:19.195719+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Oncotelic appoints CMO Fatih Uckun and CRO Seymour Fein effective May 1, 2022","bullets":["Fatih Uckun appointed Consulting CMO; $504k/year salary, 70% time commitment.","Seymour Fein appointed Consulting Chief Regulatory Officer; $180k/year, 10% time.","Both to lead OT-101 registration trials for DIPG and pancreatic cancer under joint venture.","Uckun previously CMO at Reven, Ares, Aptevo; Fein has 35+ years and 20+ FDA approvals."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-012308","json":"https://secwatch.observer/filing/0001493152-22-012308.json","markdown":"https://secwatch.observer/filing/0001493152-22-012308.md","text":"https://secwatch.observer/filing/0001493152-22-012308.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315222012308/0001493152-22-012308-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315222012308/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:13:19.195719+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3ca8249625","claim":"Fatih Uckun was appointed as Consulting Chief Medical Officer at Oncotelic Therapeutics, Inc..","evidence_excerpt":"On May 1, 2022, Oncotelic Therapeutics, Inc. (the “ Company ”) appointed Fatih Uckun, M.D., Ph.D. as its Consulting Chief Medical Officer for the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/908259/000149315222012308/0001493152-22-012308-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Consulting Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"88108ba72c","claim":"Seymour Fein was appointed as Consulting Chief Regulatory Officer at Oncotelic Therapeutics, Inc..","evidence_excerpt":"In addition, on May 1, 2022, the Company appointed Dr. Seymour Fein as its Consulting Chief Regulatory Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/908259/000149315222012308/0001493152-22-012308-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Consulting Chief Regulatory Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}